Pharmaceuticals | Citizens Against Government Waste
The WasteWatcher: The Staff Blog of Citizens Against Government Waste

Pharmaceuticals

They’re Baaaaack – The Sequel

In their never-ending quest to run roughshod and exert control over the research-intensive biopharmaceutical industry, socialists in Congress have introduced various price-control bills.  For some reason they continue to think innovative drugs that cure cancer or other chronic diseases, such as hepatitis C, are whipped up in a back room with a 1970s-style “

Using an International Pricing Index is NOT the Way to Lower Drug Costs

On December 6, John O’Brien, the senior advisor on drug pricing reform to Health and Human Services (HHS) Secretary Alex Azar, published a blog, entitled, “How the IPI Model Would Introduce New Market Competition to Medicare Drug Spending.”  The blog left a lot of fiscal conservatives and patient-centered, free-market healthcare advocates scratching their heads.  Mr.

New HHS Transparency Regulation Mandates Inaccurate Information

The Pharmaceutical Research Manufacturers Association (PhRMA), the trade association that represents the nation’s leading biopharmaceutical research companies, announced a new proposal on Monday regarding direct-to-consumer (DTC) television advertising.  This voluntary agreement by PhRMA members would help patients access more useful information about the cost of their medicines.

Importation Will Not Lower Drug Costs

Citizens Against Government Waste (CAGW) was disappointed to see that the Trump Administration announced on Thursday, July 19, that the Food and Drug Administration (FDA) is exploring ways to import lower cost drugs from foreign countries.  Since most countries utilize price controls to determine a drug’s cost, the U.S.

President Trump’s Blueprint to Lower Drug Costs: A Lot to Unpack

On Friday, May 11, President Trump released his report on what his administration will do to lower drug costs.

President Trump's Drug Costs Proposals Coming Soon

The President has already made some good policy decisions and has offered other proposals that will help to lower drug costs.

Stealing Patents Won’t Bring Down Drug Costs

On February 15, 2018, 18 Democratic members of Congress sent a letter to Health and Human Services (HHS) Secretary Alex Azar, asking him to use his authority under 28 U.S.C.

Drug Prices - The Council of Economic Advisers and Trump Administration Weigh In

Last Friday, on February 9, 2018, the White House Council of Economic Advisers released a 30-page report on, “Reforming Biopharmaceutical Pricing at Home and Abroad.”  There is enough in the report to please or give heartburn to all the players in the pharmaceutical distribution chain but, there are many significant ideas that policy makers should and will consider.  President Trump’s administration has already done so for its 2019 budget proposal, which will be discussed briefly in this blog.

Taxpayers and Patients Win First Round on 340B Drug Discount Rule

Citizens Against Government Waste (CAGW) discussed in its November 7, 2017 WasteWatcher blog, a Centers for Medicare and Medicaid Services (CMS) final rule for Medicare Part B that will lower costs to taxpayers and Medicare beneficiaries for certain outpatient pharmaceuticals purchased under the 340B drug discount program.

Rogue "Drug" Companies Face Congress

On Thursday, February 4, the House Committee on Oversight and Government Reform held a hearing entitled, “Developments in the Prescription Drug Market.”

Pages

Sign Up for Email Updates!Click Here!

View Archives

Posts by Author

Posts by Tag

Big Government (152) Obamacare (78) Waste (74) Congress (74) Healthcare (71) Budget (69) Uncategorized (56) Telecommunications (50) Internet (48) Technology (46) Deficit (43) Debt (43)